BioCentury
ARTICLE | Clinical News

Tyme reports Phase Ib/II data for TYME-88 in prostate cancer

June 23, 2017 8:24 PM UTC

Tyme Technologies Inc. (OTCQB:TYMI) reported interim data from 8 evaluable patients with recurrent, non-metastatic prostate cancer in a 6-month Phase Ib/II trial showing that oral TYME-88 (SM-88, SM88) led to a radiographic progression-free survival (PFS) rate of 100%. Additionally, 7 patients achieved a significant reduction in circulating tumor cells (CTCs) and all 8 patients achieved stabilization or improvement in prostate-specific antigen (PSA; KLK3) doubling time. No patient required subsequent toxic therapy and no dose-limiting toxicities (DLTs) or treatment-related serious adverse events were reported. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

The open-label, dose-escalation, dose-expansion, U.S. trial is evaluating PFS, the effect of TYME-88 on CTCs, PSA doubling time, biomarkers, safety and patient-reported outcomes...